None listed
Conditions
Interventions
Drug : After undergoing radiofrequency catheter ablation, patients will be randomly assigned to either a group receiving oral anticoagulants (NOACs such as Lixiana, Eliquis, Rivaroxaban, Pradaxa, or w
Sponsors
The Catholic University of Korea, Seoul St. Mary's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who have undergone radiofrequency catheter ablation for paroxysmal or persistent atrial fibrillation, are aged between 19 and 74 years, have a CHADS-VASc score of 0 or 1, and are able to voluntarily provide informed consent to participate in the clinical study.
Exclusion criteria
Exclusion criteria: Presence of intracardiac thrombus on transesophageal echocardiography performed prior to the procedure, or a history of major bleeding events (e.g., intracranial hemorrhage, gastrointestinal bleeding) before the procedure.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Occurrence of thrombosis | — |
Secondary
| Measure | Time frame |
|---|---|
| Occurrence of bleeding | — |
Countries
Korea, Republic of
Contacts
Public ContactHyejin shin
The Catholic University of Korea, Seoul St. Mary's Hospital
Outcome results
None listed